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1 Institute for Experimental Medical Research (DETAE), Genetics Department, Istanbul, Turkey
2 Department of Internal Sciences, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
3 Department of Basic Oncology, Oncology Institute, Hacettepe University, Ankara Turkey
4 Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Bilkent, Ankara, Turkey
SOCS-1, an important protein in the JAK/STAT pathway, has a role in the down stream of BCR-ABL protein ki-
nase. We investigated 56 CML patients and 16 controls for the methylation status of SOCS-1 gene promoter and
Exon 2 regions. Exon 2 was found to be methylated in 58.9% of the patients and 93.8% of the controls [P 5
0.020, OR 5 0.121(0.015–0.957)%95CI]. The promoter region was found unmethylated in all patient samples and
controls. Although previous studies revealed a relation between SOCS1 gene Exon-2 hypermethylation and
CML development or progression, the results of this study showed no such correlation. On the contrary, our
results might be indicating hypomethylation in CML patients, this hypothesis need to be studied in larger study
population. Am. J. Hematol. 82:729–730, 2007. VC 2007 Wiley-Liss, Inc.
Introduction
SOCS-1 is a member of SOCS (Suppressor of Cytokine
Signaling) protein family. Like the other members of this fam-
ily, suppression activity of SOCS-1 is cytokine specific (leuke-
mia inhibiting factor, interferon g, growth hormone and prolac-
tin) [1]. This mechanism works as a negative regulator.
When SOCS-1 is stimulated by a cytokine, the expression
level increases and binds directly to the JAK/STAT complex
and inhibit the stimulation [2]. JAK/STATs are also implicated
in the downstream of BCR-ABL protein, which activates the
JAK/STAT pathway by its constitutive tyrosine kinase activity
[3]. It has been shown that the BCR-ABL induces the STAT5
activation, which leads to leukemogenesis [4]. Loss of
SOCS1 gene could play an important role in the regulation
and progression of leukomogenesis in CML. Thus, we aimed
to study the methylation status of SOCS1 gene, which has




Peripheral blood and/or bone marrow samples were collected from
56 CML patients, (33 male, 23 female) and 16 (7 male, 9 female)
healthy controls. The mean ages were 46.85 ± 15.41 and 30.37 ± 8.6
for patients and controls, respectively. All patients were found to be
t(9;22) positive by cytogenetics and molecular genetics analysis meth-
ods at the time of diagnosis. The ethical committee of Cerrahpasa
Medical Faculty approved this study and informed consent was
obtained from all patients and controls.
Bisulphate Treatment and MS-PCR
Following the DNA isolation NaBiS treatment was performed as
described previously [8]. NaBiS treated DNA was purified by the Gene
Clean III Kit (Q-Biogene) according to the instructions. After the bisul-
phate treatment, the samples were amplified both for the promoter and
Exon 2 regions by MS-PCR. The primers for the promoter region was
reported previously [6] and Exon 2 primers were redesigned by us. The
PCR yields were analyzed on 4% agarose gel.
Results and Discussion
Methylation markers are not only shown in solid tumors
but are also shown in hematological malignancies like AML
and CML.
In this study, 56 CML samples and 16 controls were ana-
lyzed for the SOCS-1 promoter and Exon 2 methylation sta-
tus. Thirty-three (58.9%) samples were methyated and 23
(41.1%) were unmethylated in CML group (Table I) and 15
(93.8%) were methylated and one was (6.3%) unmethylated
in control group [P 5 0.09, OR 10.455 (1.289–84.785) 95%
CI]. In our study we found that the Exon 2 region were
methylated in 15 of 16 control samples. Johan et al. also
studied the same region and found methylation in healthy
controls [9]. Our results are in concordance with Johan et al.
and both results support that the Exon 2 is not a relevant
region to study SOCS-1 methylation status and the results
can be misleading.
We also studied the promoter region of SOCS1 gene in
CML samples and controls. No methylation was detected in
patient or control groups for the promoter region. Liu et al.
studied SOCS1 promoter methylation in CML group [10]
and they revealed 52% of methylation. Although, in both
studies the same region was analyzed in CML patients with
the primers designed from the same CpG island, the out-
come was found to be different. The possible reasons for
this discrepancy might be due to the following differences;
selection of CpG island prediction methods, PCR specificity
and efficiency, patient selection criteria and sampling time
points.
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According to the results of this study there is no correla-
tion between SOCS1 methylation and CML development or
progression. Since the methylation status of Exon 2 is
much higher in healthy controls (15/16) than in patients
(33/56) a hypomethylation status could be speculated in
the studied region. In the next step, this hypothesis should
be studied in a wide range of healthy individuals and the
results with gene expression and mutation analyses need
to be confirmed.
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Diagnostic sample 6 3
Follow up sample 27 20
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